At the present time, the direction of change of the plasma free fatty acid (FFA) level is considered to serve as an index to the pattern of fat metabolism, representing an indicator of the balance between fat storage and fat mobilization. In to 2-deoxyglucose-6-phosphate (2-DG-6-P), and it has been postulated that the 2-DG-6-P may compete for transport into the cell with glucose-6-phosphate (3). The purpose of this study was to observe the effect of 2-DG administration on FFA levels in normal human subjects and to study in addition the effect of glucose, insulin, fructose and lactate upon the pattern of response to 2-DG.
At the present time, the direction of change of the plasma free fatty acid (FFA) level is considered to serve as an index to the pattern of fat metabolism, representing an indicator of the balance between fat storage and fat mobilization. In the fasting, nonexercising individual, a rising plasma FFA level suggests net fat mobilization and a falling FFA level suggests net fat storage. If the status of carbohydrate metabolism does relate to fat metabolism, then plasma FFA levels may be expected to change in a number of experimental situations. Dole Was the first to (lemonstrate that glucose and insulin administration decreased fasting FFA levels (1) and Bierman, Dole and Roberts that patients with diabetes niellitus have high FFA levels (2) . Experimental inteference with carbohydrate metabolism might also be expected to influence plasma FFA levels. The availability of 2-deoxy-D-glucose (2-DG) has made it possible to test this hypothesis. 2-DG is phosphorylated to 2-deoxyglucose-6-phosphate (2-DG-6-P), and it has been postulated that the 2-DG-6-P may compete for transport into the cell with glucose-6-phosphate (3) . The purpose of this study was to observe the effect of 2-DG administration on FFA levels in normal human subjects and to study in addition the effect of glucose, insulin, fructose and lactate upon the pattern of response to 2-DG.
MATERIALS AND METHODS
2-DG was purchased in the chemically pure form from the Nutritional Biochemicals Corporation. The compound was dissolved in distilled water, passed through a Seitz filter, and stored in a sterile container for intravenous administration. Aliquot samples were tested for bacterial contamination. solution and stored in the cold. For intravenous administration the final volume was made up to 100 ml with normal saline.
Plasma glucose was measured by the Nelson modification of the Somogyi method (4), which also determines blood 2-DG levels. 2-DG levels were not specifically determined in these experiments but have been previously reported following the administration of a comparable amount of compound to humans. The 2-DG plasma levels rarely exceed 10 mg per 100 ml (5). FFA was measured by the method of Dole (1) as modified by Trout, Estes and Friedberg (6) . Plasma lactate was measured by the Barker-Summerson method (7) . Urinary epinephrine and norepinephrine levels were measured by the bioassay technique of von Euler (8) .
Eleven subjects were selected for these studies on the basis of normal body build and no evidence of metabolic or endocrine abnormality. The subj ects were either medical students or hospital patients with minor illnesses. All subjects were studied in the morning after a 12 hour overnight fast. On entering the laboratory, they were placed in bed and remained recumbent and quiet for the duration of the study. Needles were placed in a vein of each arm, one for the intravenous infusion of 2-DG, the other for sampling. Each sample consisted of 10 ml of blood drawn into heparinized syringes and immediately placed on ice prior to centrifugation in the cold. Two or three pre-infusion samples were drawn starting at 10 minutes after placement of the needles. The 2-DG was infused at a constant rate over a 30 minute period. The total dose was 60 mg per kg in all but two studies (one with 50 mg per kg and one with 70 mg per kg). Blood samples were then drawn at 5 to 15-minute intervals during the first hour of the experiment and at 30-minute intervals after that period. The experiments lasted approximately 3 to 4 hours. Signs and symptoms of drug effect were recorded in each instance. These included sweating, somnolence, hunger, and occasionally, nausea and restlessness. In no instance were the symptoms sufficiently disturbing to the subject to warrant discontinuing the study.
In the studies of sodium lactate, this compound was infused intravenously at various (lose levels before, durinig or after the attainment of a clinical 2-DG effect. In other experiments, 25 or 50 g of glucose and 22 g of fructose were given intravenously after a 2-DG effect was apparent. Hyperglycemic-free insulin (HGF) was also studied in doses up to 8 Figure 1 , the pattern of response of glucose levels shortly after the infusion was begun was linear and steel). During the period of linear rise of plasma glucose it is possible to make an approximate calculation of the rate at which glucose is being added to the total body water by way of glycogenolytic and gluconeogenetic processes. This is based on the previous finding that during 2-DG infusion glucose utilization is negligible (5) and that any rise in plasma glucose must be primarily due to glucose production by way of glycogenolysis and gluconeogenesis. In the subject depicted in Figure 1 , during a half-hour period of nearly linear glucose rise (0-30 minutes after completing the infusion), the plasma glucose concentration changed 32 mg per 100 ml. For a calculated average total body water compartment of 60 per cent of body weight, this plasma concentration increase represents the addition of 26.7 g of glucose per hour. fore, during and after 2-DG infusion (Table II) . There was a striking increase in epinephrine excretion in all studies. Because of the proportionality method involved in the bioassay procedure, the norepinephrine levels could not be accurately assessed in'the presence of such large amounts of epinephrine. Accordingly, in two experiments norepinephrine levels were not calculated. In the other two experiments the levels tended to fall.
DISCUSSION
These studies are considered to provide further evidence for the thesis that the status of carbohydrate metabolism is an important determinant of the equilibrium of fat metabolism. Following 2-DG infusion, the sharp rise in FFA levels that occurred in the fasted, resting individual suggests a net increase in fat mobilization as compared with fat synthesis and utilization. (9) . Data on the utilization of FFA by specific tissues samples in vitro in the presence of 2-DG have not been reported. Studies in this laboratory using C14-labeled palmitate do not indicate any effect of 2-DG on the rate of disappearance of infused FFA in human subjects (10) .
The FFA level rise observed in these studies might represent a response to 2-DG infusion which is mediated by lipid mobilizing processes present only in the intact subject. The symptoms of drowsiness, hunger and marked sweating suggest the response recognized as the one attending hypoglycemia. In the presence of 2-DG, although the measured plasma level of glucose is high, if cellular utilization of glucose cannot occur the organism can be considered to be functionally hypoglycemic. The relative unavailability of glucose to the central nervous system might then initiate the usual response of the organism to hypoglycemia which characteristically includes adrenal medullary secretion. Epinephrine and norepinephrine are both known to raise plasma FFA levels and to have an in vitro lipolytic property (1, 11, 12) . In the studies reported here, the marked increases in urinary epinephrine excretion and the immediate rise in plasma glucose level that follows the 2-DG infusion would be consistent with the hypothesis that the FFA level rises are mediated by a mechanism involving the adrenal medulla.
Significant rises in plasma glucose invariably follow 2-DG infusion and sometimes persist for 6 to 8 hours. In this experimental situation, when glucose utilization is markedly blocked, the amount of net glucose added to the body water may be calculated. This net increment of glucose most likely represents both glucose release by way of glycogenolysis and glucose elaboration by the process of gluconeogenesis. Values of 9 to 90 g of glucose per hour were obtained by such calculations. The magnitude of these figures approximates, and in some instances exceeds, those estimates of Bearn, Billing and Sherlock (13, 14) and of Werk and associates (15) .
The symptoms experienced as a result of the 2-DG infusion were reversed by the administration of glucose but not by insulin, although the FFA rise was equally well reversed by both procedures. The protective effect of glucose on 2-DG toxicity, as well as the failure of insulin to protect against 2-DG toxicity, has also been observed in mice (16) . The lack of reversal by insulin may be due to the reduction of serum glucose subsequent to insulin injection. In this experimental situation the FFA level is being modified by an insulin-sensitive tissue (adipose), but the 2-DG effects on the central nervous system are occurring in an insulin-insensitive tissue (the brain).
Finally, with the thesis in mind that the key role of glucose metabolism in governing FFA levels might be concerned with glucose serving as a source of glycerol for the esterification of free fatty acids, lactate infusions were given so as to provide an alternate source of three carbon compounds. In our study of a series of lactate infusions at varying dosage levels and at different times with relation to 2-DG administration, we were unable to demonstrate any reversal of the plasma FFA response to 2-DG. However, Mueller who independently found that 2-DG infusions in dogs caused consistent plasma FFA rises, noted that the administration of lactate reversed the FFA rise (17) . Our failure to demonstrate a similar lactate reversal effect in man may be due to the different dosages employed, or else to the species difference in the handling of lactate and the degree to which exogenous lactate is available to esterify fatty acids. SUMMARY 1. 2-Deoxy-D-glucose (2-DG), a competitive inhibitor of glucose metabolism, was administered intravenously to a series of fasting, rested subjects.
2. Plasma levels of free fatty acid (FFA), glucose and lactate increased markedly following the infusion of 2-DG.
3. Insulin, glucose and fructose reversed the rise in plasma FFA but did not alter plasma lactate levels. Lactate infusion did not alter the FFA or glucose response to 2-DG. Insulin also reversed the glucose rise following 2-DG but not the clinical side effects.
4. Marked increases in urinary excretion of epinephrine accompany and follow the infusion of 2-DG and suggest that the mechanism mediating the plasma FFA response may involve the adrenal medulla.
5. 
